ENXTBR:TUB

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide.

Rewards

PE ratio (13.1x) is below the Belgian market (13.9x)

Earnings grew by 13.2% over the past year

Risk Analysis

No risks detected for TUB from our risk checks.


Snowflake Analysis

Proven track record and fair value.

Share Price & News

How has Financière de Tubize's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TUB has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.1%

TUB

0.4%

BE Pharmaceuticals

3.0%

BE Market


1 Year Return

33.8%

TUB

7.7%

BE Pharmaceuticals

-20.1%

BE Market

Return vs Industry: TUB exceeded the Belgian Pharmaceuticals industry which returned 7.7% over the past year.

Return vs Market: TUB exceeded the Belgian Market which returned -20.1% over the past year.


Shareholder returns

TUBIndustryMarket
7 Day-1.1%0.4%3.0%
30 Day-8.5%-6.7%-1.3%
90 Day16.0%-3.3%13.8%
1 Year34.7%33.8%11.1%7.7%-18.8%-20.1%
3 Year38.6%35.9%29.9%14.9%-24.0%-28.6%
5 Year50.3%45.7%30.2%7.7%-13.1%-22.5%

Price Volatility Vs. Market

How volatile is Financière de Tubize's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Financière de Tubize undervalued compared to its fair value and its price relative to the market?

13.11x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: TUB (€78.3) is trading above our estimate of fair value (€10.88)

Significantly Below Fair Value: TUB is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: TUB is good value based on its PE Ratio (13.1x) compared to the XE Pharmaceuticals industry average (22.2x).

PE vs Market: TUB is good value based on its PE Ratio (13.1x) compared to the Belgian market (13.9x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TUB's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TUB is good value based on its PB Ratio (1.3x) compared to the BE Pharmaceuticals industry average (3.1x).


Next Steps

Future Growth

How is Financière de Tubize forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Financière de Tubize has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Financière de Tubize performed over the past 5 years?

10.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: TUB has high quality earnings.

Growing Profit Margin: Insufficient data to determine if TUB's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: TUB's earnings have grown by 10.1% per year over the past 5 years.

Accelerating Growth: TUB's earnings growth over the past year (13.2%) exceeds its 5-year average (10.1% per year).

Earnings vs Industry: TUB earnings growth over the past year (13.2%) exceeded the Pharmaceuticals industry 11.2%.


Return on Equity

High ROE: TUB's Return on Equity (9.8%) is considered low.


Next Steps

Financial Health

How is Financière de Tubize's financial position?


Financial Position Analysis

Short Term Liabilities: TUB's short term assets (€1.8M) do not cover its short term liabilities (€32.8M).

Long Term Liabilities: TUB has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: TUB's debt to equity ratio (1.2%) is considered satisfactory.

Reducing Debt: TUB's debt to equity ratio has reduced from 8.6% to 1.2% over the past 5 years.

Debt Coverage: TUB's operating cash flow is negative, therefore debt is not well covered.

Interest Coverage: Insufficient data to determine if TUB's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Financière de Tubize current dividend yield, its reliability and sustainability?

0.79%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: TUB's dividend (0.79%) isn’t notable compared to the bottom 25% of dividend payers in the Belgian market (2.51%).

High Dividend: TUB's dividend (0.79%) is low compared to the top 25% of dividend payers in the Belgian market (5.33%).


Stability and Growth of Payments

Stable Dividend: TUB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are stable.

Growing Dividend: TUB is not paying a notable dividend for the Belgian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: TUB is not paying a notable dividend for the Belgian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TUB's dividend in 3 years as they are not forecast to pay a notable one for the Belgian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average board tenure


CEO

Financière de Tubize has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Gaëtan Hannecart
President & Chairman of the Board0.33yr€7.00kno data
Daniel Janssen
Honorary Chairmanno datano data13.21%
€ 460.5m
Diégo du de Bergendal
Director9.33yrs€6.00k11.22%
€ 391.2m
Annick Van Overstraeten
Independent Director1.33yrs€7.00kno data
Cyril Janssen
Director9.33yrs€7.00kno data
Charles-Antoine Emmanuel Janssen
Member of the Board of Directors9.33yrs€4.00kno data
Cédric Van Rijckevorsel
Director7.33yrs€7.00kno data
Nicolas Janssen
Director6.33yrs€7.00kno data
Fiona de Hemptinne
Director6.33yrs€6.00kno data
Cynthia d'Echallens
Director6.33yrs€6.00kno data
Marc Speeckaert
Director2.33yrs€7.00kno data
Bruno Holthof
Independent Director0.33yrno datano data

6.3yrs

Average Tenure

62.5yo

Average Age

Experienced Board: TUB's board of directors are considered experienced (6.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Financière de Tubize SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Financière de Tubize SA
  • Ticker: TUB
  • Exchange: ENXTBR
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €3.485b
  • Shares outstanding: 44.51m
  • Website: https://www.financiere-tubize.be

Location

  • Financière de Tubize SA
  • Allee de la Recherche 60
  • Brussels
  • Brussels
  • 1070
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TUBENXTBR (Euronext Brussels)YesBearer SharesBEEURJan 1992
0D53LSE (London Stock Exchange)YesBearer SharesGBEURJan 1992
FTDDB (Deutsche Boerse AG)YesBearer SharesDEEURJan 1992
TUBBBATS-CHIXE (BATS 'Chi-X Europe')YesBearer SharesGBEURJan 1992
FTDBST (Boerse-Stuttgart)YesBearer SharesDEEURJan 1992

Biography

Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immuno ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/15 04:59
End of Day Share Price2020/08/14 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.